Arana superhumanises CSL
Friday, 06 June, 2008
Arana (ASX: AAH) and CSL (ASX: CSL) have completed their second collaborative research project together, paving the way for CSL to develop new pharmaceuticals.
A lead antibody from the CSL pharmaceutical pipeline was run through Arana's Superhumanisation technology, which converts murine antibodies into a humanised form. It was further optimised for affinity using Arana's EvoGene technology platform.
As well as the one-off payment for completing the research, Arana will also be entitled to royalties if CSL choose to develop one of the modified antibodies for clinical testing.
This is the second time CSL and Arana have collaborated, and the third collaborative project Arana has completed.
Arana's stock price has remained relatively stable despite the announcement.
Scientists uncover how cancer cells hide from immune system
By targeting the RNA helicase known as DDX6, scientists could enable the immune system to...
Vanillin flavouring in vapes may disrupt embryo development
Vanillin — a common flavouring chemical in e-cigarettes — may disrupt the normal...
Heart valve tissues created from stem cells
The breakthrough should help advance our understanding into how human heart valves develop,...
